Carvedilol: The new role of beta blockers in congestive heart failure

American Family Physician

Volumn 58, Issue 7, 1998, Pages 1627-1639

  Vanderhoff, Bruce T ^a   Ruppel, Heather M ^a   Amsterdam, Peter B ^b  

^a Grant Family Practice Residency   (United States)

^b GRANT MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CARVEDILOL;

ARTICLE; BETA ADRENERGIC RECEPTOR BLOCKING; CONGESTIVE HEART FAILURE; DRUG EFFECT; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; MORTALITY; PROGNOSIS; TREATMENT INDICATION;

ADRENERGIC BETA-ANTAGONISTS; CARBAZOLES; DRUG INTERACTIONS; HEART FAILURE, CONGESTIVE; HUMANS; PROPANOLAMINES; SEVERITY OF ILLNESS INDEX; VENTRICULAR FUNCTION, LEFT;

EID: 0032212995     PISSN: 0002838X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. Eichhorn EJ. Do beta-blockers have a role in patients with congestive heart failure? Cardiol Clin 1994;12:133-42.
2. Effects of carvedilol, a vasodilator-beta-blocker, in patients with congestive heart failure due to ischemic heart disease. Circulation 1995;92:212-8.
3. Sharpe N. Beta-blockers in heart failure. Future directions. Eur Heart J 1996:17(Suppl B):39-42.
4. Sackner-Bernstein JD, Mancini DM. Rationale for treatment of patients with chronic heart failure with adrenergic blockade. JAMA 1995;274:1462-7 [Published erratum in JAMA 1996;275:686].
5. Cohn JN. The management of chronic heart failure. N Engl J Med 1996;335:490-8.
6. Eichhorn EJ, Bristow MR. Practical guidelines for initiation of beta-adrenergic blockade in patients with chronic heart failure [Editorial]. Am J Cardiol 1997;79:794-8.
7. Packer M. Beta-blockade in the management of chronic heart failure. Eur Heart J 1996;17(Suppl B):21-3.
8. Waagstein F. The role of beta-blockers in dilated cardiomyopathy. Curr Opin Cardiol 1995;10:322-31.
9. Neubauer GE, Gaudron P, Horn M, Hu K, Tian R, Krahe T. Beta-blockers in cardiac failure. Eur Heart J 1994;15(Suppl C): 16-24.
10. Kjekshus J, Swedberg K. Treatment of heart failure. J Intern Med 1996;239:335-43.
11. Pfeffer MA, Stevenson LW. Beta-adrenergic blockers and survival in heart failure [Editorial]. N Engl J Med 1996;334:1396-7.
12. Hash TW 2d, Prisant LM. Beta-blocker use in systolic heart failure and dilated cardiomyopathy. J Clin Pharmacol 1997;37:7-19.
13. Chen BP, Chow MS. Focus on carvedilol: a novel beta-adrenergic blocking agent for the treatment of congestive heart failure. Formulary 1997;32(8): 795-805.
14. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med 1992;327:685-91.
15. Pfeffer MA, Braunwald E, Moye LA, Basta L, Brown EJ Jr, Cuddy TE, et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. N Engl J Med 1992;327:669-77.
16. Packer M, Bristow MR, Cohn JN, Colucci WS, Fowler MB, Gilbert EM, et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. N Engl J Med 1996;334:1349-55.
17. Colucci WS, Packer M, Bristow MR, Gilbert EM, Cohn JN, Fowler MB, et al. Carvedilol inhibits clinical progression in patients with mild symptoms of heart failure. Circulation 1996;94:2800-6.
18. Cohn JN, Levine TB, Olivari MT, Garberg V, Lura D, Francis GS, et al. Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure. N Engl J Med 1984;311:819-23.
19. Levine TB, Francis GS, Goldsmith SR, Simon AB, Cohn JN. Activity of the sympathetic nervous system and renin-angiotensin system assessed by plasma hormone levels and their relation to hemodynamic abnormalities in congestive heart failure. Am J Cardiol 1982;49:1659-66.
20. Waagstein F, Bristow MR, Swedberg K, Camerini F, Fowler MB, Silver MA, et al. Beneficial effects of metoprolol in idiopathic dilated cardiomyopathy. Lancet 1993;342:1441-6.
21. Gilbert EM, Anderson JL, Deitchman D, Yanowitz FG, O'Connell JB, Renlund DG, et al. Long-term beta-blocker vasodilator therapy improves cardiac function in idiopathic dilated cardiomyopathy: a double-blind, randomized study of bucindolol versus placebo. Am J Med 1990;88:223-9.
22. Bristow MR, O'Connell JB, Gilbert EM, French WJ, Leatherman G, Kantrowitz NE, et al. Dose-response of chronic beta-blocker treatment in heart failure from either idiopathic dilated or ischemic cardiomyopathy. Circulation 1994;89:1632-42.
23. The Cardiac Insufficiency Bisoprolol Study (CIBIS). A randomized trial of beta-blockade in heart failure. Circulation 1994;90:1765-73.
24. Olsen SL, Gilbert EM, Renlund DG, Taylor DO, Yanowitz FD, Bristow MR. Carvedilol improves left ventricular function and symptoms in chronic heart failure: a double-blind randomized study. J Am Coll Cardiol 1995;25:1225-31.
25. Metra M, Nardi M, Giubbini R, Dei Cas L. Effects of short- and long-term carvedilol administration on rest and exercise hemodynamic variables, exercise capacity and clinical conditions in patients with idiopathic dilated cardiomyopathy. J Am Coll Cardiol 1994;24:1678-87.
26. Krum H, Sackner-Bernstein JD, Goldsmith RL, Kukin ML, Schwartz B, Penn J, et al. Double-blind, placebo-controlled study of the long-term efficacy of carvedilol in patients with severe chronic heart failure. Circulation 1995;92:1499-506.
27. Packer M, Colucci WS, Sackner-Bernstein JD, Liang CS, Goldscher DA, Freeman I, et al. Double-blind, placebo-controlled study of the effects of carvedilol in patients with moderate to severe heart failure. Circulation 1996;94:2793-9.
28. Randomised, placebo-controlled trial of carvedilol in patients with congestive heart failure due to ischaemic heart disease. Lancet 1997;349:375-80.
29. Moye LA, Abernethy D. Carvedilol in patients with chronic heart failure [Letter]. N Engl J Med 1996;335:1318.
30. von Olshausen K, Pop T, Berger J. Carvedilol in patients with chronic heart failure [Letter]. N Engl J Med 1996;335:1318-9.
31. Carvedilol. In: Drug facts and comparisons. St. Louis: Facts and Comparisons, 1997:901-4.
32. Cohn JN, Archibald DG, Ziesche S, Franciosa JA, Harston WE, Tristani FE, et al. Effect of vasodilator therapy on mortality in chronic congestive heart failure. N Engl J Med 1986;314:1547-52.
33. Nichols AJ, Gellai M, Ruffolo RR Jr. Studies on the mechanism of arterial vasodilation produced by the novel antihypertensive agent, carvedilol. Fundam Clin Pharmacol 1991;5:25-38.
34. Yue TL, Cheng HY, Lysko PG, McKenna PJ, Feuerstein R, Gu JL, et al. Carvedilol, a new vasodilator and beta adrenoceptor antagonist, is an antioxidant and free radical scavenger. J Pharmacol Exp Ther 1992;263:92-8.
35. Ruffolo RR Jr, Gellai M, Heible JP, Willette RN, Nichols AJ. The pharmacology of carvedilol. Eur J Clin Pharmacol 1990:38(Suppl 2):82-8.
36. Cleland JG, Swedberg K. Carvedilol for heart failure, with care. Lancet 1996;347:1199-201.
37. Hauf-Zachariou U, Widmann L, Zulsdorf B, Hennig M, Lang PD. A double-blind comparison of the effects of carvedilol and captopril on serum lipid concentrations in patients with mild to moderate essential hypertension and dyslipidaemia. Eur J Clin Pharm 1993;45:95-100.
38. Carvedilol (Coreg). Package insert. Philadelphia: SmithKline Beecham Pharmaceuticals, May 1997.